Management Team

Global Blood Therapeutics has assembled a team of employees, directors and scientific founders rich in scientific experience and capabilities in drug discovery, development and commercialization. Our management has a successful track record in developing and commercializing drug candidates in a wide range of therapeutic areas. We intend to leverage this expertise and experience to further advance our development pipeline.

Ted W. Love, M.D.
Chief Executive Officer

Dr. Love has more than 20 years of broad leadership and management experience in the pharmaceutical industry. Dr. Love most recently served as executive vice president, research and development and technical operations at Onyx Pharmaceuticals, where he played an instrumental role in initiating and completing several of Onyx’s first Phase 3 clinical trials. Prior to Onyx, Dr. Love served as president, chief executive officer and chairman of Nuvelo, Inc., where he led growth of the company to a market capitalization of $1 billion, and previously served as senior vice president, development at Theravance, Inc. Earlier in his career, Dr. Love held roles of increasing responsibility in medical affairs and product development at Genentech. As vice president, product development, Dr. Love oversaw the development strategy and execution leading to approvals of Rituxan, Herceptin, Xolair, TNKase, Raptiva and Avastin. Dr. Love has served as a consultant in medicine at Massachusetts’s General Hospital in the department of cardiology. Dr. Love currently sits on the board of directors of Amicus Therapeutics and Cascadian Therapeutics (formerly Oncothyreon). Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. Dr. Love completed his residency in internal medicine and fellowship in cardiology at the Massachusetts General Hospital.

Jeffrey Farrow
Chief Financial Officer

Mr. Farrow joined GBT in 2016. Mr. Farrow has led finance, risk management and investor relations for several public biotech companies as they evolved from discovery and development to commercial stage. Mr. Farrow previously served as CFO of ZS Pharma, Inc., which was acquired by AstraZeneca in December 2015 for $2.7 billion. Prior to ZS Pharma, he was CFO at Hyperion Therapeutics, Inc., where he led Hyperion’s initial public offering and follow-on offering and was part of the team responsible for the successful regulatory approval and commercial launch of RAVICTI® for the treatment of urea cycle disorders. He previously served as vice president of finance at Evotec AG. Prior to Evotec, Mr. Farrow served as vice president of finance and chief accounting officer at Renovis, which was acquired by Evotec AG. Earlier in his career, Mr. Farrow spent seven years working in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University at Fullerton and is a certified public accountant (inactive).

Jung E. Choi
Chief Business and Strategy Officer

Ms. Choi joined GBT in April 2015 and is responsible for spearheading the company’s business development activities and corporate strategy, including identifying and executing strategic transactions to drive corporate value. In addition, Ms. Choi oversees our patient advocacy activities. During her career, Ms. Choi has led or managed over 50 transactions exceeding $13 billion in value. She most recently served as senior vice president, corporate development for InterMune, Inc. during the company’s acquisition by and integration into Roche/Genentech. From 2011 to 2013, Ms. Choi led corporate and business development for Chimerix, Inc. as its senior vice president, corporate development. She also spent nearly a decade at Gilead Sciences, holding various management positions including leadership of business development, licensing, and mergers and acquisition activities. During her tenure, she built and oversaw the corporate development group, and played a leading role in Gilead’s numerous licensing transactions and company acquisitions. Ms. Choi also led the U.S. commercial launch of Hepsera® for the treatment of hepatitis B virus. She also possesses venture capital and strategy experience having previously served as vice president at Bay City Capital and as engagement manager at McKinsey & Company. Ms. Choi received an undergraduate degree in human biology, as well as an M.B.A. from Stanford University.

Tricia Suvari
Chief Legal Officer

Ms. Suvari has approximately 20 years of experience in the life sciences industry. She previously served in several senior roles at CV Therapeutics, ultimately as senior vice president, general counsel and chief compliance officer. At CV Therapeutics, she led the in-house legal team as the company transitioned from an R&D-stage company to a commercial-stage company with marketed products in the US and EU and multiple partnering arrangements. Prior to CV Therapeutics, she served as senior counsel at Genentech, where she completed many complex business development and licensing transactions and advised on legal compliance for several commercial products. She has also served as an independent consultant, supporting biopharmaceutical companies ranging from early-stage private companies to public companies. Most recently before joining GBT, Ms. Suvari served as a vice president and general counsel at the non-profit Peninsula Open Space Trust, where she led the land transactions team responsible for negotiating, structuring and funding complex conservation-oriented real estate transactions. Ms. Suvari earned her Bachelor of Sciences degree in Geology and Geophysics from Yale University and her J.D. degree from Harvard Law School.

Hing Sham, Ph.D.
Senior Vice President, Research

Dr. Sham joined Global Blood Therapeutics as senior vice president, chemistry in July 2014. Dr. Sham brings more than 30 years of experience to Global Blood Therapeutics, achieving major accomplishments in pharmaceutical research and discovery throughout his career. During a 24-year tenure at Abbott Laboratories, culminating in his appointment as a distinguished research fellow in global pharmaceutical discovery, Dr. Sham and his team discovered and advanced 10 clinical candidates spanning cardiovascular disease, HIV, oncology and diabetes. Among his numerous discoveries, Dr. Sham is the co-inventor of Norvir® and the primary inventor of Kaletra®, Abbott Laboratories’ first and second-generation HIV protease inhibitors approved for the treatment of HIV. Dr. Sham was named a Hero of Chemistry in 2003 by the American Chemical Society for improving children’s health and wellness. After his tenure at Abbott, Dr. Sham served as senior vice president of research and head of chemical sciences at Elan Pharmaceuticals. While at Elan, Dr. Sham led the chemistry team in the discovery of two clinical candidates for the treatment of Alzheimer’s disease. Most recently, Dr. Sham was head of research and development at iOneWorldHealth/PATH.org, a non-profit pharmaceutical development organization. Dr. Sham has published more than 180 scientific articles in peer-reviewed journals and is a named inventor on 81 issued U.S. patents. Dr. Sham received his Ph.D. in synthetic organic chemistry from the University of Hawaii and completed his post-doctoral training in the department of chemistry at Indiana University.

Peter Radovich
Senior Vice President, Operations

Mr. Radovich joined GBT in November 2014 and is responsible for the company’s program management, technical operations, commercial strategy and quality assurance functions. Mr. Radovich has more than 15 years of biotechnology industry experience. Most recently, he served as Vice President of Program Leadership at Onyx Pharmaceuticals, a subsidiary of Amgen, where he led the company’s global, cross-functional product team responsible for the development and commercialization of Kyprolis®. Prior to this role, he held a variety of roles of increasing responsibility in Onyx’s commercial organization supporting Kyprolis® and Nexavar®. During his tenure at Onyx, he was a key member of the deal team for Onyx’s acquisition of Proteolix. Prior to Onyx, he was at Chiron Corporation (now Novartis) in product marketing supporting Proleukin® (interleukin-2) in multiple oncology indications. Mr. Radovich holds a B.A. in biology and chemistry from Texas Christian University and an M.B.A. from Washington University.